Grant: Master's Award: Canada Graduate Scholarships
University of Calgary
$17,500.00
Effects of Proviral Integration Site for Moloney Murine Leukemia Virus (PIM) Kinases and Zipper Interacting Protein Kinase (ZIPK) inhibition on the development of colonic inflammation and fibrosis
FY 2016-17
Summary
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), affects 1 in every 150 Canadians. The chronic inflammation is associated with fibrosis and stricture development, a complication that necessitates surgery for ~50% of Crohn's patients; also, nearly 1/3 of CD patients require a second intestinal resection within 10 years. Despite advances in developing therapeutics to control chronic intestinal inflammation, no effective anti-fibrotic therapies exist for IBD patients. My project aims to study the effects of inhibiting proviral integration sites for Moloney murine leukemia virus kinases (PIMKs) and zipper-interacting protein kinase (ZIPK) on the development of colonic inflammation and fibrosis. PIMKs have been shown to play an important role in T helper cell proliferation, as well as promoting the production of pro-inflammatory chemical messengers (cytokines). ZIPK’s involvement in epithelial-mesenchymal cell transition, with increasing expression of biomarkers associated with fibrosis and stricture development, was also demonstrated in a recent publication. Nevertheless, PIMKs’ contribution to the pathogenesis of and intervention against IBD is not well-defined. Furthermore, there has been no examination of ZIPK in terms of its effects on IBD to date. The discovery of highly potent and dual specific PIMK/ZIPK inhibitors by the MacDonald Lab and their international collaborators represents an opportunity for the development of novel IBD therapeutics. The goal of this project is to examine the utility of these novel inhibitor compounds for the attenuation of intestinal inflammation and fibrotic development in experimental models of IBD.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
367067
Name
Chen Tina H
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Effects of Proviral Integration Site for Moloney Murine Leukemia Virus (PIM) Kinases and Zipper Interacting Protein Kinase (ZIPK) inhibition on the development of colonic inflammation and fibrosis
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cell Differentiation; Cell Proliferation; Chronic Inflammation; Epithelial-Mesenchymal Transition; Fibrosis; Inflammatory Bowel Disease (Ibd); Intestinal Epithelial Barrier; Pim Kinases; T Helper Cells; Zipper-Interacting Protein Kinase (Zipk)
Abstract
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), affects 1 in every 150 Canadians. The chronic inflammation is associated with fibrosis and stricture development, a complication that necessitates surgery for ~50% of Crohn's patients; also, nearly 1/3 of CD patients require a second intestinal resection within 10 years. Despite advances in developing therapeutics to control chronic intestinal inflammation, no effective anti-fibrotic therapies exist for IBD patients. My project aims to study the effects of inhibiting proviral integration sites for Moloney murine leukemia virus kinases (PIMKs) and zipper-interacting protein kinase (ZIPK) on the development of colonic inflammation and fibrosis. PIMKs have been shown to play an important role in T helper cell proliferation, as well as promoting the production of pro-inflammatory chemical messengers (cytokines). ZIPK’s involvement in epithelial-mesenchymal cell transition, with increasing expression of biomarkers associated with fibrosis and stricture development, was also demonstrated in a recent publication. Nevertheless, PIMKs’ contribution to the pathogenesis of and intervention against IBD is not well-defined. Furthermore, there has been no examination of ZIPK in terms of its effects on IBD to date. The discovery of highly potent and dual specific PIMK/ZIPK inhibitors by the MacDonald Lab and their international collaborators represents an opportunity for the development of novel IBD therapeutics. The goal of this project is to examine the utility of these novel inhibitor compounds for the attenuation of intestinal inflammation and fibrotic development in experimental models of IBD.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chen, Tina H
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~